T he Patient-Centered Outcomes
Research Institute (PCORI), which recently marked its third anniversary, has established distinctive pathways for funding and conducting practical research and a solid foundation of funded studies. The PCORI board of governors has adopted three strategic goals to meet its mandate under the Affordable Care Act. These goals are to increase the quantity, quality, and timeliness of usable, trustworthy comparative research information; to accelerate the implementation and use of research evidence; and to exert influence on research funded by others to make it more patient-centered and useful. To address the first goal, PCORI funds comparative clinical effectiveness research (CER) 1,2 related to five national priorities: evaluating prevention, diagnosis, and treatment options; improving health systems; enhancing communication and dissemination of evidence; addressing disparities in health and health care; and improving CER methods and data infrastructure.
To ensure that funded research is useful and therefore more likely to be implemented, PCORI engages individuals and organizations representing patients, caregivers, clinicians, delivery systems, payers and purchasers, researchers, policymakers, and industry in generating research questions. Multistakeholder advisory panels help PCORI prioritize and refine suggested questions for targeted proposal solicitations. 3 We require funding applicants to involve patients and relevant stakeholders on their research teams throughout the study -helping to identify and refine research questions, choose comparators and outcomes, identify and recruit study populations, develop recruitment materials and survey instruments, and interpret and disseminate findings. Patients and other stakeholders, trained by PCORI in research review, make up 50% of the merit-review panels that evaluate applications -the idea being to keep the focus on relevant questions and lay a foundation for disseminating important findings.
Applications are scored on technical merit, including adherence to standards developed by PCORI's Methodology Committee; the relevant condition's burden on individuals and society; the relevance to patients of the proposed comparisons, study populations, and outcomes (patientcenteredness); the quality of patient and stakeholder engagement; and the likelihood that the results could change clinical or personal practice, improving outcomes. Patient-centeredness, engagement, and likelihood of changing practice are not explicit criteria of either the National Institutes of Health or the Agency for Healthcare Research and Quality and are meant to produce a different portfolio of funded projects.
Recognizing the pervasive lack of the type of information needed for decision making, the board has solicited CER proposals spanning the spectrum of clinical conditions. After issuing broad funding announcements for each national priority, PCORI has awarded more than $316 million for 192 studies covering a wide range of clinical conditions, geographic locations, and socioeconomic characteristics (see table for examples; a complete list of funded projects is available at www.pcori.org/pfaawards/?viewby =priority).
We have also begun to issue funding announcements targeting specific research questions. The first such announcement, sponsored with the National Institute on Aging, requests proposals for a large clinical trial comparing a multicomponent intervention with usual care for preventing injurious falls in the elderly. The second calls for proposals to assess treatment options for black and Hispanic patients with uncontrolled asthma. The third, jointly sponsored with the Agency for Healthcare Research and Quality, seeks proposals for a registrybased cohort study comparing the effectiveness of various uterinesparing treatment options in women with symptomatic uterine fibroids. Targeted announcements allow PCORI to direct resources to areas deemed high-priority by stakeholders and advisory panels.
To increase the efficiency of conducting patient-centered CER Key requirements for awardees include the active involvement of host health systems and patients in governing and using the infrastructure, a willingness to host system-based randomized studies, and a willingness to collaborate with outside researchers on PCORI-funded research.
More recently, PCORI announced its first 30 "Pipeline to Proposals" Engagement Awards, 4 intended to seed new partnerships between researchers and stakeholder communities and build teams that can compete successfully for patient-centeredresearch funding from PCORI and other sources.
PCORI's broad funding announcements have yielded a diverse research portfolio reflecting the major causes of illness and death in the United States. Of 162 CER studies, 37 (23%) focus on cancer detection, treatment, or surveillance; 30 (19%) on mental health; 26 (16%) on cardiovascular diseases; and 18 (11%) on endocrine disorders, including diabetes mellitus. Crosscutting issues, including self-care (15 studies) and pain management (7 studies), are also represented. PCORI-funded studies include many direct comparisons of two or more options and many others that synthesize existing evidence, then develop and evaluate decision support tools for improving patient-clinician decision making. Nearly 45% of studies feature prospective, randomized comparisons. Studies typically include patient-reported outcomes or other patient-relevant outcomes, often in addition to more traditional outcomes such as rehospitalization, disease progression, or the occurrence of complications or death.
PCORI has found stakeholder communities ready and able to engage in research. Patient-centered questions come from multiple sources, and innovative partnerships are emerging. Participation in merit review has been received well by both scientific and stakeholder reviewers; because the unfamiliar processes of collaborating with stakeholders have presented challenges to some researchers, PCORI conducted a webinar entitled "Promising Practices in Engagement" 5 and made examples of successful engagement plans available online. Some successful applicants build on long-standing relationships with patients, clinicians, or organizations representing them; others develop new relationships as proposals are prepared. Patient and family advisory councils of delivery systems or health plans are frequent partners, as are professional, provider, and payer associations.
Over the next 3 years, PCORI will commit as much as $1.5 billion to research projects. Broad funding announcements will continue, but we'll increasingly focus on high-priority questions identified by PCORI advisory panels through targeted PFAs and calls for larger pragmatic studies. We continue to refine our merit-review processes and will seek ways to support new investigators in conducting patient-centered outcomes research. The interests of patients with rare diseases will be pursued with an advisory panel. PCORI will also seek additional opportunities to cofund and comanage clinical research with others.
PCORI will disseminate its methodology standards, work with the research community in developing additional needed standards, and work with a clinical trials advisory panel to enhance PCORI-funded clinical trials. Finally, we will actively evaluate the effectiveness of and best methods for engaging patients and other stakeholders in research -a fundamental requirement of PCORI research that, though reasonable and appealing, needs a firmer evidence base.
PCORI has laid an innovative foundation for producing and disseminating clinical research, engaging multiple stakeholders in the process, and embedding clinical research within health care systems and activated patient communities. Ultimately, our aim is to make research more useful and more likely to be included in health care decision making.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. D uring my cardiology fellowship, I worked at a women's cardiovascular clinic where we asked every new patient the same question: "What do you think is the number-one killer of women?" Most women said either breast cancer or heart disease. But Ms. S., a middle-aged woman with high blood pressure and hyperlipidemia, answered in a way that sticks with me: "I know the right answer is heart disease," she said, eyeing me as if facing an irresistible temptation, "but I'm still going to say 'breast cancer.'" If helping women understand their cardiovascular risk were about right answers, I would simply have reiterated the facts about heart disease -that it takes more women's lives each year than all types of cancer combined (see graphs), that it is in many ways preventable, and that, despite what many women believe, multivitamins and antioxidants do not reduce the risk. But Ms. S.'s response short-circuited my statistical litany. Her sense of risk was clearly less about fact than about feeling.
Would more facts really address those feelings?
Data on campaigns to educate women about heart disease reinforced my sense that our efforts to provide women with the facts about heart disease were missing something critical. Although the first decade of educational campaigns led to a near doubling of women's knowledge about heart disease, in the past few years such efforts have failed to reap further gains. Moreover, persistent gaps in perceptions remain among minority women, who are often at greatest risk. 1 If the next frontier in preventing cardiovascular disease among women is less about disseminating evidence than about understanding why the evidence may be hitting a wall, the critical question is why women might feel more fearful of other diseases, particularly breast cancer, despite ample evidence suggesting that heart disease poses a far greater threat.
"Misfearing," the term Cass Sunstein uses to describe the human tendency to fear instinctively rather than factually, is not unique to women's perceived health threats. 2 Decades of research on risk perception have revealed the many factors feeding our misfears and associated perceptions. Tornadoes. Terrorist attacks. Homi cides. The big, the dramatic, and the memorable occupy far more of our worry budget than the things that kill with far greater frequency: strokes, diabetes, heart disease. But interacting with many of these fear factors is another force we rarely associate with our individual health perceptions: our commitment to our cultural groups.
Our desire to belong to something bigger than ourselves is as fundamental to our nature as our desire for individual success. Human nature is both selfish and "groupish," according to the moral psychologist Jonathan Haidt: "Our minds contain a variety of mental mechanisms that make us adept at promoting our group's interests. . . . We are not saints, but we are sometimes good team players." 3 If you survived middle school, you know how powerful the desire to belong to a group can be.
